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Tumor necrosis factor-a (TNF-a) is a major proinflammatory cytokine and involved in the etiology of psoriasis.
The 238G4A and 308G4A polymorphisms influence the transcription of the TNF-a gene and have been
implicated in psoriasis risk. However, the results from the published studies on the association between TNF-a
polymorphisms and psoriasis risk are conflicting. Our meta-analysis of a total of 997 psoriasis cases and 943
control subjects from eight published case–control studies for the 238G4A polymorphism and of 1,156
psoriasis cases and 1,083 control subjects from 10 published case–control studies for the 308G4A
polymorphism showed that a significantly increased risk was associated with the variant GAþAA genotypes
of 238G4A, compared with the GG genotype (odds ratio (OR) 2.60, 95% confidence interval (95% CI)
1.48–4.56), whereas a significantly reduced psoriasis risk was associated with the variant GAþAA genotypes of
the 308G4A compared with the GG genotype (OR 0.57, 95% CI 0.45–0.71). Our findings suggest that TNF-a
238G4A and 308G4A polymorphisms might be used as biomarkers for psoriasis risk prediction. A single
larger study with thousands of subjects and biochemical and biological characterization is warranted to
evaluate further the role of 238G4A and 308G4A polymorphisms and psoriasis risk in a population of
various ethnicities.
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INTRODUCTION
Psoriasis is a common skin inflammatory disorder affecting
2–3% of the general population worldwide (Koo, 1996).
Although the precise etiology of psoriasis is still unclear, it is
known that the epidermis and dermis are infiltrated by
leukocytes in the psoriatic lesions, where increased levels
and activity of proinflammatory cytokines, such as tumor
necrosis factor (TNF)-a, are detected (Gilhar et al., 1996;
Ackermann and Harvima, 1998; Lowes et al., 2005; Rozieres
et al., 2006).
The TNF-a gene has been located in chromosome 6p21.3,
which is only 250 kb centromeric from the human leukocyte
antigen-B. Recent resequencing studies revealed at least 44
gene polymorphisms in the TNF-a gene (http://egp.gs.
washington.edu/data/ tnf/tnfxx.csnps.txt). Two G-to-A transi-
tions in the promoter region at the –238 and –308 sites
appeared to influence TNF-a expression and have been
considered as functional single-nucleotide polymorphisms
(Wilson et al., 1992; Pociot et al., 1995). Several recent
studies have suggested (Kaluza et al., 2000) that the
functional polymorphisms in the –238 and –308 sites are
associated with the development of psoriasis (Arias et al.,
1997; Balding et al., 2003; Chang et al., 2003; Hashigucci
et al., 2003; Mossner et al., 2005; Baran et al., 2006;
Schmeling et al., 2006). Although considerable effort and
resources have been put into the study of the association
between TNF-a gene polymorphisms and psoriasis risk,
results are conflicting instead of consistent. Some studies
found a significant association between TNF-a polymorph-
isms at 238 and 308 and psoriasis, whereas others failed
to get any such association.
Owing to the small sample size and other limitations in the
study design, a single study is more likely to have been
underpowered to detect the effects of the polymorphisms of
TNF-a; a quantitative synthesis to accumulate data from
various studies may provide evidence for the association of
genetic polymorphisms with disease risk. Therefore, we
performed this meta-analysis to obtain a relatively intrinsic
summary of estimates for the association of the TNF-a
238G4A and 308G4A polymorphisms with psoriasis
risk as well as to quantify the potential between-study
heterogeneity.
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RESULTS
Meta-analyses databases
We established a database according to the extracted
information from all the literature. Table 1 lists the psoriasis
type of the study, ethnicity of the population, numbers of
cases and controls, and variant allele frequency for TNF-a
238G4A and 308G4A polymorphisms. There are eight
case–control studies with 997 cases and 943 controls
concerning TNF-a 238G4A polymorphisms and 10 case–-
control studies with 1,156 cases and 1,083 controls
concerning TNF-a 308G4A polymorphisms. All studies
indicated that the distribution of genotypes in the controls
was consistent with Hardy–Weinberg equilibrium (goodness
of fit w2 test, degree of freedom (df)¼1). However, only
50.0% of the studies had a statistical power 480% based on
the disease risk (odds ratio (OR)) calculated from the data for
238G4A polymorphisms (Arias et al., 1997; Hohler et al.,
1997; Long et al., 2004; Mossner et al., 2005) and only one
study had a statistical power 480% for 308G4A
polymorphisms (Mossner et al., 2005). A classical manual
PCR–restriction-fragment length polymorphism or single-
strand conformation polymorphism assay was performed in
70.0% of the studies, dot-blotting was used in one study
(Hohler et al., 1997), and sequenced genotyping was carried
out in one other study (Long et al., 2004). Only one study
used another genotyping assay to validate the data (Chang
et al., 2003).
Quantitative synthesis
In the eligible psoriasis patients and control subjects, there
were significant differences in terms of the 308G4A variant
A frequencies between the two major ethnicities (Caucasian
13.3%, Asian 5.61%; Po0.001) but not in terms of the
–238G4A polymorphisms (Caucasian 4.69%, Asian 4.54%;
P¼0.964). Figure 1a shows the psoriasis risks associated with
the TNF-a 238G4A GAþAA genotype compared with the
GG genotype. Overall, individuals carrying the GAþAA
genotype had a significantly increased psoriasis risk
compared with the individuals with the GG genotype (OR
2.60, 95% confidence interval (CI) 1.48–4.56) and this
association was also observed in the Caucasian subgroup
(OR 3.89, 95% CI 2.50–6.05). However, in Asians, we found
only a nonsignificant effect for the TNF-a 238G4A variant
genotype on psoriasis risk (OR 1.46, 95% CI 0.66–3.09)
(Figure 1a). For 308G4A variant polymorphisms, we
found an overall significantly reduced risk for psoriasis (OR
0.57, 95% CI 0.45–0.71). In addition, this significant
association was also observed in subgroups stratified by
ethnicity (OR 0.59, 95% CI 0.46–0.76 for Caucasians and OR
0.48, 95% CI 0.30–0.79 for Asians) (Figure 2a). Furthermore,
we studied the associations between the psoriasis risk and the
TNF-a 238G4A and 308G4A polymorphisms stratified
by the subtype of psoriasis (i.e., types I and II) in a smaller
data set, because some of the studies did not provide the
information on the genotype distribution for each type of
psoriasis. For both the 238G4A and the 308G4A
polymorphisms, the results in the type I and II subgroups
were very consistent with those from the studies of all types of
psoriasis. For the 238G4A polymorphism, OR 3.28, 95%
CI 1.42–7.55, for type I patients and OR 3.11, 95% CI
1.11–8.71, for type II patients (Figure 1b); for the 308G4A
polymorphism, OR 0.66, 95% CI 0.48–0.91, for type I
patients and OR 0.57, 95% CI 0.37–0.88, for type II patients
(Figure 2b).
Test of heterogeneity
There was significant heterogeneity among the studies for
238G4A (w2¼ 23.42, df¼7, P¼ 0.001) but not for the
Table 1. Study characteristics and variant allele prevalence from published studies on the relation of TNF-a
polymorphisms to psoriasis risk
TNF-a 238G4A TNF-a 308 G4A
Cases
Variant allele
frequency in Cases
Variant allele
frequency in
First
author Year
Country and Racial
descent Total Type I Type II Controls controls Total Type I Type II Controls controls
Baran 2006 Poland/Caucasian ND — — ND NC 78 54 24 74 0.122
Mossner 2004 Germany/Caucasian 239 — — 135 0.044 239 — — 135 0.152
Long 2004 China/Asian 77 48 29 82 0.018 77 48 29 82 0.067
Tsunemi 2003 Japan/Asian 163 — — 96 0.011 163 — — 96 0.021
Kim 2003 Korea/Asian 103 80 23 125 0.060 103 80 23 125 0.072
Chang 2003 China/Asian 105 56 49 160 0.069 105 56 49 160 0.046
Craven 2001 UK/Caucasian ND — — ND NC 81 48 33 66 0.174
Reich 1999 Germany/Caucasian 151 100 51 123 0.049 151 100 51 123 0.179
Arias 1997 Germany /Caucasian 99 64 35 123 0.049 99 64 35 123 0.183
Hohler 1997 Germany/Caucasian 60 60 0 99 0.035 60 60 0 99 0.162
NC, not calculated; ND, not done; TNF, tumor necrosis factor; — , data not available.
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–308G4A polymorphism studies (w2¼3.78, df¼9,
P¼0.93). Moreover, in the subgroups of different popula-
tions, we found no heterogeneity for –238G4A (w2¼6.71,
df¼4, P¼0.15 for Caucasian and w2¼6.74, df¼ 3, P¼0.08
for Asian) or –308G4A (w2¼2.02, df¼ 5, P¼ 0.85 for
Caucasian and w2¼ 1.27, df¼ 3, P¼ 0.74 for Asian) in either
population. When we further evaluated the source of
heterogeneity for the AAþGA genotype (vs GG genotype)
by ethnicity, we observed a heterogeneity for ethnicity for the
–238G4A polymorphism (w2¼ 16.74, df¼1, Po0.001).
Publication bias
In the funnel plot analysis of publication bias (contrast of
GAþAA genotype plotted against the precision), the shape of
the funnel plot seems asymmetrical both for 238G4A and
308G4A polymorphisms, suggesting that the larger esti-
mate of the association belongs to the smaller study, whereas
the larger study shows little effect (Figure 3). An Egger test
was used to provide statistical evidence for funnel plot
symmetry (Egger et al., 1997). In the linear regression
analysis, the intercept value provides a measure of asym-
metry – the larger its deviation from 0, the more pronounced
the asymmetry. We observed the intercept values of 2.06 for
238G4A and 2.43 for 308G4A, which significantly
deviated from 0 (t¼5.90, Po0.001 for 238G4A and
t¼ 2.54, P¼0.035 for 308G4A).
DISCUSSION
We performed a meta-analysis to detect the association of
functional single-nucleotide polymorphisms in the promoter
region at the 238 and 308 sites of the TNF-a gene with
psoriasis risk. We found an overall at-risk effect for the
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Figure 1. ORs (log scale) of psoriasis associated with TNF-a –238G4A for the AAþAG genotype compared with the GG genotype. For each study, the
estimate of OR and its 95% CI is plotted with a box and a horizontal line. ~, pooled OR and its 95% CI. (a) Stratified by ethnicity. (b) Stratified by type of the
psoriasis.
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238G4A variant genotypes but a protective effect for the
308G4A variant genotypes compared with the wild
homozygous genotypes. Considering the relatively small
sample size, our result in relation to these polymorphisms
should be treated as preliminary. Nevertheless, to the best of
our knowledge, this is the first meta-analysis of case–control
studies evaluating the association of TNF-a gene polymorph-
ism with the risk of psoriasis vulgaris.
Psoriasis vulgaris is an inflammatory dermatosis, which
has a very complex genetic basis (Ameen, 2003; Jullien and
Barker, 2006; Piruzian and Abdeev, 2006). The TNF-a gene
has been suggested to be a major susceptibility gene
candidate in immune-mediated disorders, including psoriasis
vulgaris (Griffiths et al., 2006). Many studies have investi-
gated the possible associations between the two most widely
studied promoter polymorphisms (i.e., 238G4A and
308G4A) and psoriasis vulgaris risk in various populations
(Kim et al., 2003; Mossner et al., 2005). However, results
from different studies have been inconsistent, probably
because of the limitations inherent in the published studies.
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Figure 2. ORs (log scale) of psoriasis associated with TNF-a –308G4A or the AAþAG genotype compared with the GG genotype. For each study, the
estimate of OR and its 95% CI is plotted with a box and a horizontal line. ~, pooled OR and its 95% CI. (a) Stratified by ethnicity. (b) Stratified by type
of the psoriasis.
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Specifically, most of the studies had a very small sample size
and did not have adequate power to detect the possible risk
for TNF-a polymorphisms. In addition, selection bias seems
unavoidable and might have played a role in the result. Next,
demographic parameters were not well matched and were
statistically adjusted in the studies. Finally, genotype mis-
classifications may have influenced the results because the
quality control of genotyping was not well done in most of
the studies.
Therefore, reliable knowledge of the influence of TNF-a
polymorphisms on psoriasis risk is needed and it may be
helpful in identifying persons at high risk of developing
psoriasis. Until now, no meta-analysis on the association
between TNF-a gene polymorphisms and risk for psoriasis
vulgaris had been done. A meta-analysis was performed on
TNF-a gene polymorphisms and their association with
psoriasis arthritis (Rahman et al., 2006). It was found that
the 238G4A polymorphism was associated with a
significantly increased risk for psoriasis (OR 2.29, 95% CI
1.48–3.55), but there was a nonsignificantly reduced risk with
the 308G4A polymorphism (OR 0.92, 95% CI 0.70–1.21).
In this study, the results for the 238G4A polymorphism
were consistent with those of Rahman et al. (2006). However,
for the 308G4A polymorphism, we also found a significant
result in both Caucasians and Asians. Because only 7–42% of
the patients with psoriasis vulgaris had psoriasis arthritis (Moll
and Wright, 1973), it is conceivable that psoriasis vulgaris
and psoriasis arthritis have some differences in genetic
background and this, hence, may lead to a discrepancy
between our study and that of Rahman et al. (2006).
The TNF-a 238G4A and 308 G4A polymorphism
association with altered psoriasis risk is most probably owing
to the variant-mediated abnormal gene expression. Some
studies have revealed that patients carrying the TNF-a
238G4A and 308G4A polymorphisms had a different
TNF-a expression in vitro (Wilson et al., 1997; Kaluza et al.,
2000). However, it seems more complex than that because
increased TNF-a expression can cause psoriasis; alternatively,
decreased TNF-a secretion could cause an impaired clear-
ance of skin infections with Candida or streptococci and
predispose individuals to the development of psoriasis
(Kaluza et al., 2000). Indeed, we found the 238G4A
variant associated with an increased psoriasis risk, whereas
the 308G4A variant is protective in this meta-analysis.
Exactly how these single-nucleotide polymorphisms work to
influence risk for psoriasis remains unknown; the variant
alleles could be either functional themselves or in linkage
disequilibrium with other functional or disease-causing
alleles involved in the etiology of psoriasis. Recently, a
strong association with psoriasis was reported for the human
leukocyte antigen Cw6-B57-DR7 haplotype in Caucasians
(Biral et al., 2006). TNF-a 238G4A and 308G4A
polymorphisms are in linkage disequilibrium and only
250 kb centromeric from human leukocyte antigen-B. Hence,
it is difficult to tell whether the polymorphisms themselves or
linked genes are responsible for our observed association.
Therefore, functional studies and larger studies are needed to
confirm these findings.
Moreover, it is well known that patients with types I and II
psoriasis have different genetic backgrounds. The human
leukocyte antigen association is very strong in type I but not
in type II psoriasis (Jullien and Barker, 2006; Piruzian and
Abdeev, 2006). However, for the TNF-a gene polymorphism
studies, the results were not consistent across studies. Some
of the studies found that there were significant differences in
the associations between TNF-a 238G4A and 308G4A
polymorphisms with psoriasis risk in type I and II psoriasis
(Arias et al., 1997; Reich et al., 1999), whereas others
failed to find any such differences (Craven et al., 2001; Baran
et al., 2006). In the present meta-analysis, we did not find
TNF-a 238G4A or 308G4A to be associated signifi-
cantly with different psoriasis risks between type I and type II
psoriasis patient subgroups. Instead, we found that, in both
types of psoriasis patients, the TNF-a 238G4A and
308G4A polymorphisms had effects similar to those in
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Figure 3. Funnel plot analysis to detect publication bias. Each point
represents a separate study for the indicated association. For each study, the
OR is plotted on a logarithmic scale against the precision (the reciprocal of
the SE). If bias is absent, small studies will have ORs that are widely scattered
but still centered around the OR estimates provided by large, more precise
studies. (a) For TNF-a –238G4A polymorphism. (b) For TNF-a –308G4A
polymorphism.
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the all-patient population. Nevertheless, as some of the
studies did not provide the information on subtype classifica-
tion, this result was obtained from a smaller data set, which
might cause bias unavoidably; therefore, this result should be
interpreted cautiously and needs to be verified in further
studies.
We detected significant heterogeneity among the studies
for 238G4A polymorphisms and further found that the
source of heterogeneity was from ethnicity, which suggests
that some certain effects of the genetic polymorphisms are
population specific. However, because no study on an
African population has been done, further research is
necessary to validate this finding. Moreover, we found
publication bias for the association between both the
238G4A and the 308G4A polymorphisms and psoriasis
risk; the studies with relatively small sample size were more
likely be associated with an increased psoriasis risk, which
brought an avoidable bias to the overall effect of the TNF-a
polymorphisms on psoriasis risk in our study.
In summary, this study found a significantly increased
psoriasis risk associated with TNF-a 238G4A and a
reduced psoriasis risk with 308G4A polymorphism. Also,
we found the 238 variant genotype playing roles in psoriasis
risk in an ethnicity-related manner. A single, larger study with
thousands of mixed-ethnicity subjects and tissue-specific
biochemical and biological characterizations is required in
the future to confirm our findings.
MATERIALS AND METHODS
Identification and eligibility of relevant studies
We attempted to include all the case–control association studies of
psoriasis with genotyping data for the TNF-a 238G4A or
308G4A polymorphism. Eligible studies were identified by
searching the electronic literature PubMedline for relevant reports
(last search update November 10, 2006, using the search terms
‘‘TNF-a and psoriasis’’). Additional studies were identified by a
manual search of references from original studies or review articles
on this topic. Review articles were excluded. Those studies that did
not have an appropriate case–control design or those that did not
present detailed genotyping information for the TNF-a 238G4A or
308G4A polymorphism were excluded. Only those studies
concerning psoriasis vulgaris and not other types of psoriasis (i.e.,
psoriasis arthritis) were included. Hence, the data available for this
analysis were from eight published case–control studies, including
997 psoriasis cases and 943 controls for the 238G4A polymorph-
ism (Arias et al., 1997; Hohler et al., 1997; Reich et al., 1999; Chang
et al., 2003; Kim et al., 2003; Tsunemi et al., 2003; Long et al., 2004;
Mossner et al., 2005) and 1,156 psoriasis cases and 1,083 controls
for the 308G4A polymorphism (Arias et al., 1997; Hohler et al.,
1997; Reich et al., 1999; Craven et al., 2001; Chang et al., 2003;
Kim et al., 2003; Tsunemi et al., 2003; Long et al., 2004; Mossner
et al., 2005; Baran et al., 2006).
Data extraction
Two investigators extracted data independently and reached a
consensus on all of the items. We sought the following information
from each article: author name, journal and year of publication,
country of origin, selection and characteristics of psoriasis cases and
controls, demographics, ethnicity, and genotyping information for
TNF-a 238G4A or 308G4A polymorphism (Table 1).
Meta-analysis
The risks (ORs) of psoriasis associated with the TNF-a 238G4A
and 308G4A polymorphisms were estimated for each study. We
assumed dominant effects of the variant A allele and estimated the
risk of the variant genotype GAþAA compared with the wild-type
GG homozygotes for both 238G4A and 308G4A polymorph-
isms. In addition to comparisons for total subjects, studies were
categorized into different subgroup analyses according to the
ethnicity and psoriasis type (i.e., types I and II). For each subgroup,
we estimated the between-study heterogeneity across the eligible
comparisons using the w2-based Q test (Lau et al., 1997). When
Po0.05, the heterogeneity was considered significant. Values from
single studies were combined using models of both fixed effects
(Mantel–Haenszel) and random effects (Petitti, 1994). Random
effects incorporate an estimate of the between-study variance and
tend to provide wider CIs when the results of the constituent studies
differ among themselves. In the absence of between-study hetero-
geneity, the two methods provide identical results. Inverted funnel
plots and Egger’s test were used to provide diagnosis of publication
bias (linear regression analysis; Egger et al., 1997). All analyses were
done with Statistical Analysis System software (v.8.0; SAS Institute,
Cary, NC) and Review Manage (v.4.2; Oxford, England). All the
P-values were two-sided.
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